20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Affimed NV (NASDAQ:AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13.
- Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13.
- 16 of 18 patients had achieved an objective response, with seven complete responses (CR) and nine partial responses (PR).
- 11 of 12 patients treated at the recommended phase 2 dose level of 108 cbNK cells per kg had Hodgkin Lymphoma.
- In this cohort of patients treated at the recommended phase 2 dose, 100% responded after the first treatment cycle with five CRs and seven PRs.
- Treatment was well tolerated with five reported cases of transient infusion-related reactions after the monotherapy infusions of AFM13.
- There were no serious adverse events such as cytokine release syndrome, immune cell-associated neurotoxicity syndrome, or graft-versus-host disease.
- Price Action: AFMD shares are down 2.68% at $6.54 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!